Robert W. Baird Cuts IQVIA (NYSE:IQV) Price Target to $260.00

IQVIA (NYSE:IQVGet Rating) had its price objective cut by Robert W. Baird from $266.00 to $260.00 in a research report report published on Friday, The Fly reports. They currently have an outperform rating on the medical research company’s stock.

Several other brokerages have also weighed in on IQV. Cowen initiated coverage on shares of IQVIA in a report on Tuesday, December 6th. They set an outperform rating on the stock. Barclays upped their price objective on shares of IQVIA from $215.00 to $235.00 and gave the company an overweight rating in a report on Thursday, October 27th. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of IQVIA from $290.00 to $270.00 in a report on Tuesday, October 18th. Cowen began coverage on shares of IQVIA in a report on Tuesday, December 6th. They set an outperform rating and a $251.00 price objective on the stock. Finally, Mizuho lowered their target price on shares of IQVIA from $270.00 to $250.00 and set a buy rating on the stock in a report on Thursday, November 10th. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of Moderate Buy and an average target price of $256.73.

IQVIA Price Performance

IQV stock opened at $222.14 on Friday. The firm has a market cap of $41.26 billion, a price-to-earnings ratio of 36.18, a PEG ratio of 2.31 and a beta of 1.37. The company has a quick ratio of 0.90, a current ratio of 0.90 and a debt-to-equity ratio of 2.29. IQVIA has a 12-month low of $165.75 and a 12-month high of $256.62. The company’s fifty day simple moving average is $211.79 and its 200 day simple moving average is $211.09.

IQVIA (NYSE:IQVGet Rating) last released its earnings results on Wednesday, October 26th. The medical research company reported $2.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.19 by $0.04. The business had revenue of $3.56 billion for the quarter, compared to analyst estimates of $3.55 billion. IQVIA had a net margin of 8.26% and a return on equity of 31.36%. On average, analysts expect that IQVIA will post 9.36 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. State Street Corp grew its position in shares of IQVIA by 3.8% during the 2nd quarter. State Street Corp now owns 8,622,096 shares of the medical research company’s stock valued at $1,870,909,000 after acquiring an additional 315,751 shares during the period. Alliancebernstein L.P. boosted its holdings in IQVIA by 20.1% in the 3rd quarter. Alliancebernstein L.P. now owns 5,157,158 shares of the medical research company’s stock worth $934,167,000 after buying an additional 862,222 shares during the period. Bishop Rock Capital L.P. boosted its holdings in IQVIA by 14,549.4% in the 2nd quarter. Bishop Rock Capital L.P. now owns 4,050,552 shares of the medical research company’s stock worth $18,667,000 after buying an additional 4,022,902 shares during the period. Lazard Asset Management LLC boosted its holdings in IQVIA by 0.5% in the 2nd quarter. Lazard Asset Management LLC now owns 2,910,418 shares of the medical research company’s stock worth $631,530,000 after buying an additional 13,682 shares during the period. Finally, Amundi boosted its holdings in IQVIA by 11.3% in the 2nd quarter. Amundi now owns 2,078,718 shares of the medical research company’s stock worth $440,687,000 after buying an additional 211,026 shares during the period. 86.20% of the stock is owned by institutional investors.

IQVIA Company Profile

(Get Rating)

IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Featured Stories

The Fly logo

Analyst Recommendations for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.